Search Results - "POHANKA, E"

Development of Proteinuria After Switch to Sirolimus‐Based Immunosuppression in Long‐Term Cardiac Transplant Patients by Aliabadi, A. Z., Pohanka, E., Seebacher, G., Dunkler, D., Kammerstätter, D., Wolner, E., Grimm, M., Zuckermann, A. O.

“…Calcineurin‐inhibitor therapy can lead to renal dysfunction in heart transplantation patients. The novel immunosuppressive (IS) drug sirolmus (Srl) lacks…”
Get full text

Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients by Heller, T., Van Gelder, T., Budde, K., De Fijter, J. W., Kuypers, D., Arns, W., Schmidt, J., Rostaing, L., Powis, S. H., Claesson, K., MacPhee, I. A. M., Pohanka, E., Engelmayer, J., Brandhorst, G., Oellerich, M., Armstrong, V. W.

“…The aim of this study was to determine whether plasma concentrations of the acyl (AcMPAG) and phenolic (MPAG) glucuronide metabolites of mycophenolic acid…”
Get full text

Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy by Chapman, J.R, Valantine, H, Albanell, J, Arns, W.A, Campistol, J.M, Eisen, H, Frigerio, M, Lehmkuhl, H, Marcen, R, Morris, R, Nashan, B, Pascual, J, Pohanka, E, Segovia, J, Zuckermann, A

“…Abstract While advances in immunosuppressive therapy have allowed dramatic improvements in the control of acute allograft rejection, there is still a need to…”
Get full text

Delayed graft function: Risk factors, consequences and parameters affecting outcome—results from MOST, A Multinational Observational Study by Lebranchu, Y., Halimi, J.M., Bock, A., Chapman, J., Dussol, B., Fritsche, L., Kliem, V., Oppenheimer, F., Pohanka, E., Salvadori, M., Soergel, M., Tufveson, G.

“…Delayed graft function (DGF) is a common complication after renal transplantation, and may affect graft function. The aim of this analysis was to evaluate risk…”
Get full text

Geographical prevalence, risk factors and impact of hepatitis B and C after renal transplantation by Kliem, V, Michel, U, Burg, M, Bock, A, Chapman, J, Dussol, B, Fritsche, L, Lebranchu, Y, Oppenheimer, F, Pohanka, E, Salvadori, M, Tufveson, G

“…Hepatitis B (HBV) and hepatitis C (HCV) virus infections are major risk factors affecting long-term morbidity and mortality after renal transplantation…”
Get more information

Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic) by Budde, K, Knoll, G, Curtis, J, Chan, L, Pohanka, E, Gentil, M, Seifu, Y, Marrast, A C, Neumayer, H H

“…A 12-month multicenter, double-blind trial in which maintenance renal transplant patients were randomized to remain on mycophenolate mofetil (MMF) or convert…”
Get more information

One-year posttransplant renal function is a strong predictor of long-term kidney function: results from the Neoral-MOST observational study by Salvadori, M, Rosati, A, Bock, A, Chapman, J, Dussol, B, Fritsche, L, Jeffery, J, Kliem, V, Lebranchu, Y, Oppenheimer, F, Pohanka, E, Tufveson, G

“…Peritransplant risk factors influence short-term and long-term graft survival, and 1-year serum creatinine is known to predict long-term graft survival. To…”
Get full text

New immunosuppressive drugs: an update by Pohanka, Erich

“…An increasing number of immunosuppressive drugs became available for clinical use over the past few decades. These include substances with recently recognized…”
Get full text

19: Impact of ACE-Inhibitor and Angiotensin Receptor Blocker Therapy on Development of Proteinuria after Switch to Sirolimus in Cardiac Transplant Recipients by Aliabadi, A.Z, Pohanka, E, Dunkler, D, Paireder, M.E, Mahr, S.L, Grömmer, M, Seebacher, G, Zimpfer, D, Roedler, S, Wolner, E, Grimm, M, Zuckermann, A.O

Get full text

n‐Butyrate downregulates the stimulatory function of peripheral blood‐derived antigen‐presenting cells: a potential mechanism for modulating T‐cell responses by short‐chain fatty acids by BÖHMIG, G. A., KRIEGER, P‐M., SÄEMANN, M. D., WENHARDT, C., POHANKA, E., ZLABINGER, G. J.

“…Modulation of proliferative T‐cell responses by n‐butyrate has been suggested to result from direct interference with cell cycle progression. Considering the…”
Get full text

Improved Attainment of NKF Classified Lipid Target Levels After Conversion From Cyclosporine to Tacrolimus in Renal Graft Recipients by Pohanka, E., Margreiter, R., Sparacino, V., Sperschneider, H.

“…In an open, prospective, multicenter study, stable renal graft recipients were converted to tacrolimus because of cyclosporine-related side effects…”
Get full text

Safety and Efficacy After Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium: Results of a 1-Year Extension Study by Budde, K., Knoll, G., Curtis, J., Kahana, L., Pohanka, E., Seifu, Y., Neumayer, H.H.

“…Enteric-coated mycophenolate sodium (EC-MPS) is an enteric-coated formulation of mycophenolic acid. A 12-month, multicenter, double-blind, randomized clinical…”
Get full text

Low 1-Year Cyclosporine Microemulsion Doses Are Associated With Better 5-Year Renal Graft Function: An Insight From MOST, a Multinational Observational Study by Salvadori, M., Rosati, A., Bertoni, E., Bock, A., Chapman, J., Dussol, B., Fritsche, L., Kliem, V., Lebranchu, Y., Oppenheimer, F., Pohanka, E., Tufveson, G., Soergel, M.

“…In earlier registry analyses, cyclosporine at doses of < 3 mg/kg/d at 1 year post–renal transplantation has been associated with significant graft loss or…”
Get full text

Dialysis in diabetic patients: hemodialysis and peritoneal dialysis. Pros and cons by Biesenbach, G, Pohanka, E

“…Both hemodialysis (HD) as well as peritoneal dialysis (PD), are efficient renal replacement therapies in uremic patients with and without diabetes. PD is less…”
Get more information

Malignancies in renal transplantation: an unmet medical need by Dantal, Jacques, Pohanka, Erich

“…Registry data show that there is an overall 3–5-fold increase in cancer risk in transplant recipients compared with the general population, with skin cancers…”
Get full text

Impact of Mycophenolate Mofetil Dose Posttransplantation on 12-Month Renal Function: Analysis of the MOST Database by Salvadori, M., Bock, A., Chapman, J., Dussol, B., Fritsche, L., Kliem, V., Lebranchu, Y., Oppenheimer, F., Pohanka, E., Tufveson, G., Rosati, A., Puig, X., Corbetta, G.

“…Mycophenolate mofetil (MMF) has greatly reduced the risk of acute rejection episodes (ARE) after renal transplantation, but dose reductions/withdrawals could…”
Get full text

Gastric mucormycosis due to Rhizopus oryzae in a renal transplant recipient by Winkler, S, Susani, S, Willinger, B, Apsner, R, Rosenkranz, A R, Pötzi, R, Berlakovich, G A, Pohanka, E

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Is treatment with interferon-  in renal transplant recipients still justified? by Pohanka, E., Kovarik, J.

Get full text

Magic mushrooms : hope for a 'cheap high' resulting in end-stage renal failure by FRANZ, M, REGELE, H, KIRCHMAIR, M, KLETZMAYR, J, SUNDER-PLASSMANN, G, HÖRL, W. H, POHANKA, E

Get full text

Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections by Kovarik, J, Mayer, G, Pohanka, E, Schwarz, M, Traindl, O, Graf, H, Smolen, J

“…Since infections with Herpetoviridae after kidney transplantation still remain a major clinical problem, we conducted a double-blind, placebo-controlled trial…”
Get more information